AMAG Pharmaceuticals Revenue Growth: 3.92%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMAG Revenue Growth Rankings
| Overall | 39th percentile | 2664 of 4424 |
| Sector | 38th percentile | 286 of 464 in Healthcare |
| Industry | 55th percentile | 8 of 18 in Diagnostic Substances |
AMAG Revenue Growth Range, Past 5 Years
| Minimum | -92.36% | Mar 1996 |
| Maximum | 1235% | Dec 1996 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these AMAG related companies
AMAG News
A Forward Look, The Year Ahead - Featured Research on AMAG Pharmaceuticals, Inc. and Akorn, Inc.
Feb 10, 9:00AM Marketwire
Feb 10, 9:00AM Marketwire
AMAG Pharmaceuticals (AMAG) Adds Rajiv De Silva and Gino Santini to Board
Feb 07, 4:31PM Street Insider
Feb 07, 4:31PM Street Insider
AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board
Feb 07, 4:31PM Benzinga
Feb 07, 4:31PM Benzinga
AMAG Pharmaceuticals Announces the Appointment of Two Independent Directors to its Board
Feb 07, 4:30PM Business Wire
Feb 07, 4:30PM Business Wire
UPDATE: JP Morgan Downgrades AMAG Pharmaceuticals to Underweight, Reduces PT to $12
Jan 23, 11:25AM Benzinga
Jan 23, 11:25AM Benzinga
$AMAG Downside Blowoff - 15 Minute Up Reversal - Green bar after 5 red bars
about 34 days ago by TradeIdeasQuant
about 34 days ago by TradeIdeasQuant
AMAG Pharmaceuticals (AMAG) Offers Q4 Sales Guidance Below Expectations
Jan 09, 7:33AM Street Insider
Jan 09, 7:33AM Street Insider
AMAG Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 04, 7:30AM Business Wire
Jan 04, 7:30AM Business Wire
Goldman Sachs Starts AMAG Pharmaceuticals (AMAG) at Neutral, Agrees with Management's New Plans
Dec 12, 3:46PM Street Insider
Dec 12, 3:46PM Street Insider
AMAG Pharma (AMAG), Takeda Get Marketing Approval for Feraheme in Canada
Dec 12, 7:47AM Street Insider
Dec 12, 7:47AM Street Insider
$AMAG "No serious adverse events were reported" in results of test on company's ferumoxytol
about 62 days ago by Benzinga
about 62 days ago by Benzinga
Health Canada Approves Feraheme® (ferumoxytol) to Treat Iron Deficiency Anemia in Adults with Chronic Kidney Disease
Dec 12, 7:45AM Business Wire
Dec 12, 7:45AM Business Wire
AMAG Pharmaceuticals (AMAG) Reports Preliminary Data for the Safety & Efficacy of Single Infusion of 1020 mg Ferumoxytol
Dec 12, 7:44AM Street Insider
Dec 12, 7:44AM Street Insider
If you were patient enough to hold onto $amag through the summer/fall you are up pretty nicely
about 67 days ago by DavidSchawel
about 67 days ago by DavidSchawel
$AMAG 200 Day SMA Cross - Price crossed below 200 day SMA (16.1075). Confirmed by volume.
about 87 days ago by TradeIdeasQuant
about 87 days ago by TradeIdeasQuant
AMAG Pharmaceuticals $AMAG up 4% after hiring Jefferies to explore options, including a potential sale.
about 87 days ago by Street_Insider
about 87 days ago by Street_Insider
15 breakouts: $AMAG (200-day MA + gap + base), $MXWL (stop: $17.99), $MDAS (gap). Two sub-$1. Okay mix of stocks if some are extended.
about 98 days ago by fallondpicks
about 98 days ago by fallondpicks
$AMAG terminates proposed merger with $ALTH - and there iit is - why $ALTH was halted
about 114 days ago by newnormsurvivor
about 114 days ago by newnormsurvivor
$ALTH halted, watch $AMAG - proposed merger between the 2 supposed to be discussed at AMAG shareholders meeting
about 114 days ago by newnormsurvivor
about 114 days ago by newnormsurvivor
Martin Shkreli Has Taken An Activist Position in $AMAG http://stks.co/ZrZ
about 124 days ago by insidermonkey
about 124 days ago by insidermonkey
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMAG | 15.85 | -0.37 | -2.28% | 336.02M |
| DLTR | 86.83 | -0.07 | -0.08% | 10.59B |
| ACET | 7.70 | 0.16 | 2.12% | 205.82M |
| URRE | 0.95 | -0.08 | -7.73% | 88.89M |
| CBLI | 3.09 | -0.05 | -1.59% | 109.48M |
| SILC | 17.12 | 0.12 | 0.71% | 117.96M |
| AAPL | 493.42 | 0.25 | 0.05% | 458.59B |
| BEST | 0.62 | -0.11 | -15.07% | 17.07M |
| ACAS | 8.69 | 0.15 | 1.76% | 3.00B |
| OLCB | 0.99 | -0.01 | -0.99% | 19.52M |
